首页> 外文期刊>Contemporary clinical trials >A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial)
【24h】

A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial)

机译:一项前瞻性2a期前期研究,研究用纳米刀对局灶性肾细胞癌(RCC)延迟间隔肿瘤切除术的患者进行局灶性经皮不可逆电穿孔(IRE)消融(IRENE试验)

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Focal ablation therapy is playing an increasing role in oncology and may reduce the toxicity of current surgical treatments while achieving adequate oncological benefit. Irreversible electroporation (IRE) has been proposed to be tissue-selective with potential advantages compared with current thermal-ablation technologies or radiotherapy. The aim of this pilot trial is to determine the effectiveness and feasibility of focal percutaneous IRE in patients with localised renal cell cancer as a uro-oncological tumour model.
机译:简介:局部消融治疗在肿瘤学中起着越来越重要的作用,并可能降低当前外科治疗的毒性,同时获得足够的肿瘤学益处。与当前的热消融技术或放射疗法相比,不可逆电穿孔(IRE)已被提出具有组织选择性,具有潜在的优势。该试验的目的是确定局灶性经皮IRE作为尿路上肿瘤模型在局限性肾细胞癌患者中的有效性和可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号